Abstract:Six-Transmembrane Epithelial Antigen of the Prostate 1 (STEAP1) is an emerging therapeutic target that is a member of the STEAP1-4 family of metalloreductases. We recently reported the preclinical characterization of xaluritamig (AMG 509), a STEAP1 XmAb® 2+1 T-cell engager molecule that is being developed for the treatment of prostate cancer (Nolan-Stevaux et al, 2023). Xaluritamig is designed to preferentially target tumor cells that express high levels of STEAP1. However, prostate tumor cells also express high levels of STEAP2. Here, we characterize the interactions between STEAP1 and STEAP2 in prostate cancer cell lines and the impact to xaluritamig activity. Bulk mRNA as well as single-cell gene expression data (scRNAseq) reveal a strong correlation between STEAP1 and STEAP2 expression in human prostate cancer, suggesting that the STEAP proteins may form both homotrimers and heterotrimers in prostate tumors. To test this idea, we investigated the structural behavior of STEAP1/2 trimers in human prostate cancer cell lines that endogenously express STEAP1 and STEAP2. Using xaluritamig and the parental anti-STEAP1 antibody, we show that STEAP1 primarily forms heterotrimers with STEAP2 in prostate cancer cells but can also assemble as homotrimers in the absence of STEAP2. Both STEAP1/2 heterotrimers and STEAP1 homotrimers can be targeted by xaluritamig, leading to T cell-dependent cellular cytotoxicity. Similarly, we found that anti-STEAP2 antibodies detected STEAP2 homotrimers when STEAP1 expression was ablated in cells, and that both STEAP1/2 heterotrimers and STEAP2 homotrimers were targeted by a STEAP2-specific T-cell engager molecule. We also demonstrate that neither STEAP1 nor STEAP2 significantly influences the mRNA or protein expression of the other. Our data elucidates the versatility of STEAP family members in forming both homotrimers and heterotrimers on the plasma membrane of human prostate cancer cells and the potential for therapeutic targeting with STEAP1/2-directed therapies. Characterizing the capability of existing STEAP1 or STEAP2 targeting therapeutics to bind their respective targets, whether within a homotrimer or heterotrimer, is crucial for a comprehensive understanding of the therapeutic potential of these drugs. Further research will help delineate the mechanism underlying the formation of STEAP1/2 trimers in cancer cells and continue advancing our understanding of this intriguing biological relationship. Citation Format: Cong Li, Lingming Liang, Joonhee Park, Olga Pryshchep, Binnaz Staley, Peng Li, Ben Alba, Xuan Liu, Fei Li, Gregory L. Moore, Matthew J. Bernett, Umesh Muchhal, John Desjarlais, Angela Coxon, Julie M. Bailis. Unveiling diverse trimeric forms of STEAP1 in human prostate cancer cells: Exploring STEAP1-STEAP2 interdependence for expression and plasma membrane localization [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6348.

Structural analysis of the lncRNA SChLAP1 reveals protein binding interfaces and a conformationally heterogenous retroviral insertion

A Novel RNA in Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome after Radical Prostatectomy in Clinically Localized Prostate Cancer

SChLAP1 promotes prostate cancer development through interacting with EZH2 to mediate promoter methylation modification of multiple miRNAs of chromosome 5 with a DNMT3a-feedback loop

Transcription-mediated chimeric RNAs in prostate cancer: time to revisit old hypothesis?

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1.

Long non‐coding RNA SChLAP1 regulates the proliferation of triple negative breast cancer cells via the miR‐524‐5p/HMGA2 axis

Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation

ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer

Abstract 4421: A Novel Long Non-Coding RNA Competes with Endogenous RNA and Mediates Prostate Cancer Progression

Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer

Abstract 6284: Multimoics reveal aberrant pathways and regulation of castration resistant and metastatic prostate cancer

Abstract 5897: Understanding and targeting fatty acid CoA ligase ACSL4 in human prostate cancer

LncRNA SNHG1 and RNA binding protein hnRNPL form a complex and coregulate CDH1 to boost the growth and metastasis of prostate cancer

AP001056.1, A Prognosis-Related Enhancer RNA in Squamous Cell Carcinoma of the Head and Neck

Abstract 6282: Novel androgen related gene network in prostate cancer cell model

Abstract A027: Identification and characterization of PLUTO-201, a novel lncRNA associated with prostate cancer metastasis

Abstract 6348: Unveiling diverse trimeric forms of STEAP1 in human prostate cancer cells: Exploring STEAP1-STEAP2 interdependence for expression and plasma membrane localization

The Landscape Of Rna Polymerase Ii-Associated Chromatin Interactions In Prostate Cancer

Analysis of the Androgen Receptor-Regulated Lncrna Landscape Identifies a Role for ARLNC1 in Prostate Cancer Progression

Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer

Secretory Leukocyte Protease Inhibitor is A Survival and Proliferation Factor for Castration-Resistant Prostate Cancer